Business Description
MaxCyte Inc
NAICS : 334510
SIC : 3845
ISIN : US57777K1060
Description
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.98 | |||||
| Equity-to-Asset | 0.87 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | -0.42 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 6.43 | |||||
| Beneish M-Score | 19.21 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 4.1 | |||||
| 3-Year EBITDA Growth Rate | -47.2 | |||||
| 3-Year EPS without NRI Growth Rate | -32.3 | |||||
| 3-Year FCF Growth Rate | -18.7 | |||||
| 3-Year Book Growth Rate | 60 | |||||
| Future 3-5Y Total Revenue Growth Rate | 8.52 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 17.98 | |||||
| 9-Day RSI | 27.32 | |||||
| 14-Day RSI | 32.92 | |||||
| 6-1 Month Momentum % | 48.11 | |||||
| 12-1 Month Momentum % | -19.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.65 | |||||
| Quick Ratio | 9.97 | |||||
| Cash Ratio | 9.43 | |||||
| Days Inventory | 846.07 | |||||
| Days Sales Outstanding | 78.56 | |||||
| Days Payable | 102.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -21.9 | |||||
| Shareholder Yield % | -0.44 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 88.52 | |||||
| Operating Margin % | -117.57 | |||||
| Net Margin % | -92.39 | |||||
| FCF Margin % | -61.48 | |||||
| ROE % | -15.66 | |||||
| ROA % | -13.77 | |||||
| ROIC % | -80.94 | |||||
| ROC (Joel Greenblatt) % | -116.68 | |||||
| ROCE % | -18.6 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 10.26 | |||||
| PB Ratio | 1.84 | |||||
| Price-to-Tangible-Book | 1.84 | |||||
| EV-to-EBIT | -5.37 | |||||
| EV-to-EBITDA | -5.87 | |||||
| EV-to-Forward-EBITDA | -10.6 | |||||
| EV-to-Revenue | 6.28 | |||||
| EV-to-Forward-Revenue | 5.51 | |||||
| EV-to-FCF | -10.18 | |||||
| Price-to-Projected-FCF | 5.78 | |||||
| Price-to-Net-Current-Asset-Value | 2.77 | |||||
| Price-to-Net-Cash | 3.24 | |||||
| Earnings Yield (Greenblatt) % | -18.62 | |||||
| FCF Yield % | -6.04 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MXCT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MaxCyte Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 41.289 | ||
| EPS (TTM) ($) | -0.37 | ||
| Beta | 1.61 | ||
| Volatility % | 73.65 | ||
| 14-Day RSI | 32.92 | ||
| 14-Day ATR ($) | 0.169172 | ||
| 20-Day SMA ($) | 4.2245 | ||
| 12-1 Month Momentum % | -19.44 | ||
| 52-Week Range ($) | 2.45 - 5.545 | ||
| Shares Outstanding (Mil) | 104.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MaxCyte Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MaxCyte Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
MaxCyte Inc Frequently Asked Questions
What is MaxCyte Inc(MXCT)'s stock price today?
The current price of MXCT is $3.99. The 52 week high of MXCT is $5.55 and 52 week low is $2.45.
When is next earnings date of MaxCyte Inc(MXCT)?
The next earnings date of MaxCyte Inc(MXCT) is 2024-05-07.
Does MaxCyte Inc(MXCT) pay dividends? If so, how much?
MaxCyte Inc(MXCT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers